by Amy Maxmen, KFF Health News Credit: CC0 Public DomainErin Kissane, a co-founder of the COVID Tracking Project, rolled up her sleeve for the Novavax COVID-19 vaccine in mid-October soon after it was finally recommended in the United States. Like many people with autoimmune diseases, she wants to protect herself from a potentially devastating COVID...
Novavax’s protein-based vaccine is the latest FDA-authorized COVID booster available this fall. Here’s what you should know By Sara Reardon on October 16, 2023 As the updated COVID vaccines roll out around the country, one more competitor has joined the mix. In early October the U.S. Food and Drug Administration authorized a new booster shot made by the...
Credit: Unsplash/CC0 Public Domain U.S. regulators on Wednesday authorized a booster dose of the COVID-19 vaccine made by Novavax. The Food and Drug Administration said the new booster option is for people 18 and older who can’t get the updated omicron-targeting Pfizer or Moderna boosters for medical or accessibility reasons—or who otherwise would not receive...
July 13, 2022 at 5:37 p.m. EDT The newest entry into the U.S. arsenal of coronavirus vaccines uses the oldest technology of the bunch. The four vaccines authorized by the Food and Drug Administration all teach the body’s immune system to recognize and attack the virus that causes covid-19, but each type does it a little differently....
by LAURAN NEERGAARD In this image provided by the Serum Institute of India, vials of freshly manufactured Novavax COVID-19 vaccines wait to be labeled in 2022, in Pune, India. The U.S. is getting another COVID-19 vaccine choice as the Food and Drug Administration on Wednesday, July 13, 2022, cleared Novavax shots for adults. Credit: Serum...
Ewen Callaway & Smriti Mallapaty Novavax’s protein-based vaccine relies on tried-and-tested technology. Credit: PA Images/Alamy The biotech firm Novavax has unveiled that its experimental vaccine is effective against rapidly spreading variants of the coronavirus. But its data bring good news and bad news: although the vaccine was more than 85% effective against a COVID-19 variant...
